The National Emerging Special Pathogens Training and Education Center (NETEC) – a consortium of three teaching hospitals that successfully treated patients with Ebola in 2014 – will help create and implement a nationwide plan to care for patients in future pandemics.
NETEC was tapped by the U.S. Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response (ASPR) after the COVID-19 pandemic exposed serious gaps in the nation’s health care system. More than half a million Americans have died from COVID.
To tackle the problem, NETEC has established a National Special Pathogen System (NSPS) of Care to help create a coordinated and standardized model of care across the country. The work builds on the expertise NETEC developed treating Ebola.
NETEC is a consortium of the University of Nebraska Medical Center/Nebraska Medicine; Emory University; and NYC Health + Hospitals/Bellevue. It is funded by ASPR and the U.S. Centers for Disease Control and Prevention (CDC).
“It’s clear that we need NSPS, as COVID-19 has exposed gaps in the national health care system that must be addressed to combat future pandemics,” said John Lowe, PhD, NETEC principal investigator and assistant vice chancellor for health security training and education at UNMC.
“In an environment riddled with fragmented approaches, siloed health care systems and an inability to respond efficiently, the coordinated response network of the NSPS will pave a path toward better care for patients affected by emerging special pathogens.”
Dr. Lowe said NETEC has convened an impressive group of leaders focused on innovative solutions for better health care system pandemic response. NETEC looks to gain support from key leaders in the health care and public health arenas, for whom the NSPS will be a valuable resource. Already, NETEC leverages its unique expertise, resources and experience to assess health care facility readiness, train providers, provide technical assistance and build a rapid research infrastructure to combat emerging special pathogens in the U.S.
NETEC will work with: organizations including federal government agencies like the CDC and Veterans Health Administration (VA) as well as experts in public health policy, payer insurance, health care management and delivery. Key leaders in professional societies and associations, academic institutions and medical centers, and emergency response services also will be involved in the effort. Each member will work to enable core capabilities of the NSPS system of care, which include: collaboration agreements, investment, operations, data and technology, and workforce. NETEC expects to have a strategy and implementation plan for the NSPS this summer.
Bruce S. Ribner, MD, MPH, NETEC principal investigator and professor of medicine in the Emory School of Medicine, says the establishment of the NSPS will lead to a sustained national network to address preparedness for responding to patients with serious communicable diseases.
“Over the past two decades, funding for biopreparedness in the United States has been like a roller coaster ride, with long periods of inadequate funding punctuated by short periods of large infusions of emergent funding,” said Dr. Ribner, who also is the medical director of the Emory University Hospital Serious Communicable Disease Unit. “Formulating the NSPS should stabilize that funding.”
More information on NETEC and the NSPS can be found at netec.org and nsps.org.
NETEC leverages unique expertise, resources, and experience to assess health care facility readiness, train providers, provide technical assistance, and build a rapid research infrastructure to combat emerging special pathogens in the United States. Combined with strong partnerships with federal agencies, NETEC ultimately strengthens national health care system response to COVID-19 and preparations for future emerging infectious disease threats. NETEC and the 10 U.S. Regional Emerging Special Pathogen Treatment Centers (RESPTCs) play pivotal roles in the COVID-19 response through isolating the first patients with COVID-19, rapidly conducting clinical research of COVID-19 therapeutics, and translating emerging science for rapid optimization of patient care and health care worker safety strategies.